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Abstract
Lung cancer (LC), is the most common and lethal cancer worldwide. It affects 
both sexes and in its early stages is clinically silent, until it reaches a more advanced 
stage, when it becomes highly incurable. In order to improve the high mortality 
associated with LC there has been an urgent need for screening high risk patients 
by low dose CT scan (LDCT) for the early detection of small resectable malignant 
tumors. However, while highly sensitive to detect small lung nodules, LDCT is non-
specific, resulting in a compelling need for a complementary diagnostic tool. For 
example, a non-invasive blood test or liquid biopsy, (LB), could prove quite useful 
to confirm a diagnosis of malignancy prior to definitive therapy. With the advent of 
LB becoming increasingly clinically accepted in the diagnosis and management of 
LC, there has been an explosion of publications highlighting new technologies for 
the isolation of and detection of circulating tumor cells (CTCs) and cell free tumor 
DNA (cfDNA). The enormous potential for LB to play an important role in the 
diagnosis and management of LC to obtain valuable diagnostic information via an 
approach that may yield equivalent information to a surgical biopsy, regarding the 
presence of cancer and its molecular landscape is described.
Keywords: Circulating Tumor Cells (CTCs), Cell Free Tumor DNA (ctDNA), 
Fluorescence in situ hybridization (FISH), Multiplex FISH, Cytogenetically Abnormal 
Cells (CACs), Liquid biopsy (LB), Lung Cancer (LC), Low Dose CT Scan (LDCT), 
Artificial intelligence (AI), PD-L1, ALK
1. Introduction
Until recently, the clinical application of CTCs had been largely confined to 
an FDA approved test, CellSearch®, for testing patients with advanced breast, 
colorectal and prostate cancer, which relies on immuno-magnetic capture of 
circulating cells expressing EpCAM. However, this test has not been proved to be 
optimal for sensitive recovery of CTCs in early stage LC. Currently, in order to 
make real-time decisions on how to manage LC, there are several new and emerging 
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label-free technologies for detecting CTCs which are more sensitive than the FDA 
approved test. While each platform differs in the methods that are employed for 
CTC enrichment and capture, all aim to accurately detect and enumerate CTCs [1]. 
In this chapter we present an overview of the current applications of LB, including 
both CTCs and cell free DNA (cfDNA) or circulating tumor DNA (ctDNA) for 
the detection, diagnosis and treatment of LC from early to advanced stages. We 
highlight the use of fluorescence in situ hybridization (FISH) to detect CTCs, in order 
to use these as adjunctive biomarkers, in conjunction with indeterminate nodules 
detected by LDCT scan, as a confirmatory test for early LC.
2. Incidence of lung cancer
Lung cancer (LC) is the leading cause of cancer incidence and mortality glob-
ally, with an estimation of 2.09 million new cases and 1.76 million deaths in 2018 
[2]. GLOBOCAN Data shows that in industrialized nations, there is no substantial 
difference in LC deaths in males due to high cigarette consumption rates, but that 
there is a higher mortality rate in females. In developing countries, LC remains the 
second highest cancer-related mortality for women, behind breast cancer [3]. The 
LC incidence rate of women ranks from the highest in Northern America (30.7 per 
100,000) and Western Europe (25.7 per 100,000) to the lowest in Western Africa 
(1.1 per 100,000). Even though women in China have a low prevalence of tobacco 
use, because of indoor pollution and occupational exposure [2, 4, 5], the incidence 
of LC in Chinese women also remains high (22.8 per 100,000) [2].
Because early-stage LC cases are asymptomatic, the majority of the patients are 
diagnosed with advanced disease [6]. The survival rate of stage I LC at 10 years is 
92% [7], but the five-year survival rate of advanced LC with distant metastases is 
only 5% [8]; thus, early detection is critical in reducing lung cancer mortality rate.
3. Screening by LDCT
Lung cancer screening had become a controversial topic since the late 1990s, due 
to the fact that the risks, effectiveness, and procedures of screening, including the 
Early Lung Cancer Action Program and screening programs in Japan [9–11], were 
not verified. In 2002, a randomized trial, the National Lung Cancer Screening Trial 
(NLST) was initiated in the United States. The primary study goal was to compare 
the lung-cancer mortality rate between a large cohort of subjects screened for LC by 
conventional chest radiography versus low-dose computed tomography (LDCT). 
Follow up data until 2010 indicated that screening with LDCT can significantly 
reduce the death rate from LC, compared with the radiography group, and that, for 
the high-risk population [12] the lung cancer mortality rate was reduced by 20% in 
the LDCT group. The 10-year follow-up result of the Dutch Belgian Randomized 
Lung Cancer Screening trial (NELSON) that started in 2003 also successfully 
demonstrated a 26% mortality reduction of the high-risk population in the LDCT 
screening group, compared with the usual care group without screening [13]. These 
two studies have become the pivotal studies in LC screening history that have linked 
the utility of LDCT to reduced LC mortality amongst high-risk populations [14]. 
A growing list of organizations has established guidelines for LC screening with 
LDCT based on the evidence showed by the NLST and NELSON [15–17].
However, the benefits of LC screening with LDCT have been diminished by the 
high false-positive rate, as only 3.6% of the participants with positive LDCT screening 
results were diagnosed with lung cancer in NLST [12]. The substantial application 
of LDCT to lung cancer has resulted in a dramatic increase in pulmonary nodule 
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detection in adults at high risk, without a corresponding rise in lung cancer incidence 
[18]. About 80% of the patients with positive LDCT results are classified as interme-
diate risk of LC, thus requiring follow-up to rule out malignancy [19]. For patients in 
this category, most will be required to undergo invasive biopsy to further evaluate the 
risk of malignancy. Also, more than one-third of these patients will not be diagnosed 
with LC, subjecting them to potential biopsy-related complications such as pneumo-
thorax and hemorrhage [20]. For patients who are at low-risk, repeated LDCT scans 
are required, which may be potentially harmful due to frequent radiation exposure 
[21]. In the case of ground glass nodules [GGNs], which may have an unpredictable 
clinical course, current diagnostic methods including biopsy and positron emission 
tomography (PET) are insufficient to differentiate malignant from benign nodules 
[22, 23]. Consequently, there is an urgent need for a non-invasive diagnostic tool such 
as a blood test or liquid biopsy (LB) that can evaluate the malignancy of pulmonary 
nodules in individuals with positive LDCT screening results (Figure 1a and b) by 
demonstrating the presence of circulating tumor cells (CTCs) in the blood.
Figure 1. 
(a) Schematic diagram demonstrating a hypothetical risk/benefit for lung cancer individual, undergoing LDCT 
scan with discovery of indeterminate lung nodule and complementary multiplexed FISH test performed on 
peripheral blood mononuclear cell fraction, to confirm presence of CTCs. (b) Real life example of a 55 year old 
lady with multiple nodules of uncertain etiology, and a fungal infection such as histoplasmosis was suspected. 
Multiplex 4 color FISH CTC assay performed on peripheral blood liquid biopsy showed more than 8 CTCs. 
Figure demonstrates CTCs stained with DAPI, and polysomy for 3p22.1 (three red signals) and polysomy 10q22.3 
(3 gold signals) in same cells (merged images). Subsequent fine needle aspiration and cell block showed a well 
differentiated neuroendocrine tumor (diff Quik), which was positive with synaptophysin and CD56. [24].
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4. Components of liquid biopsy
Liquid biopsies (LB) comprise circulating tumor cells (CTCs) from the 
cellular fraction of blood, and circulating tumor DNA (ctDNA), derived from 
the plasma fraction of blood (Figure 2). ctDNA originates directly from the 
tumor or CTCs, that are thought to release ctDNA via apoptosis and necrosis 
from dying cells, or active release from viable tumor cells. Both fractions have 
been shown to have potential for detecting, monitoring, and treating a variety of 
different cancers across all stages of disease. The term LB is not just confined to 
the use of tumor derived material from the blood stream and may also be applied 
to other biofluids such as urine, saliva, cerebro-spinal fluid, pleural fluid or bile 
from cancer patients, however for the purpose of this review, LB refers to the 
blood stream. Use of LB obviates the need for invasive tissue biopsies, which are 
frequently from inaccessible organ sites, and usually require the use of anesthe-
sia. Complications are not unusual, and may include hemorrhage and infection, 
while for lung biopsies, pneumothorax is not uncommon. LB is an easy to use 
approach, as a simple blood draw, requiring only 10 ml of blood, may reveal 
circulating tumor cells (CTCs), or cancer specific mutations or aberrant meth-
ylation patterns [26] in the ctDNA portion of the plasma, that are consistent with 
malignancy [27, 28].
LB may be used in order to diagnose early LC and can be easily repeated 
over time to detect relapse of cancer or minimal residual disease (MRD) fol-
lowing surgery, or to monitor a patient’s response to various chemo- biological 
or immune checkpoint therapies. The constant replenishment of CTCs and cell 
free ctDNA from the primary tumor and/or metastatic sites, enables LB to detect 
and monitor the development of new clones of CTCs that express different 
mutations, as compared to an original tissue biopsy or a preceding LB, which 
may have arisen as a response to a targeted therapy. The rate -limiting factor for 
the widespread use of LB especially in early-stage LC, has been the scarcity of 
recovery of CTCs and ctDNA. In addition, due to the wide range of different 
methodologies for detecting and capturing CTCs, as well as the lack of standard-
ization and clinical validation of different platforms, it is difficult to know which 
is the optimal platform to choose [1].
Figure 2. 
Mechanism of extravasation of CTCs and circulating tumor DNA from primary lung carcinoma into the blood 
stream. The left-hand panel shows the source of circulating tumor DNA derived from necrosis and apoptosis of 
CTCs. The right-hand panel shows the mechanism of extravasation into the blood stream via EMT [25].
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5.  Scenarios in which LB may be indicated preferentially over tissue 
biopsy
First, as a complementary test in the face of abnormal images acquired by LDCT 
screening for lung cancer, where in order to determine the etiology of an indeter-
minate pulmonary nodule, a simple blood draw demonstrating the unequivocal 
presence of circulating tumor cells (CTCs) may be useful as a decision-making tool 
for the further clinical management of the patient. In this situation, tissue biopsy 
such as fine needle aspiration (FNA), needle biopsy or endoscopic ultra-sound 
guided biopsy, may be performed, however, occasionally may be both difficult 
and dangerous to the patient due to the small size and location of the mass and 
may be non-diagnostic because of the inability to procure representative tissue for 
pathological assessment. A positive CTC test (Figure 1) will lead to the procure-
ment of an excisional surgical biopsy for standard pathological examination with 
curative intent or in other cases, patients may be candidates for stereotaxic radiation 
therapy. A negative CTC test will require follow up by LDCT, until the clinicians 
have determined that the nodule is stable and benign. However, in this scenario the 
patient will have been spared an invasive procedure for a non-malignant lesion.
Until now, current methods for detection and quantitation of CTCs have been 
time consuming and complex and require expensive instrumentation as well as a 
great deal of expertise available only at limited sites. As a result, large scale clinical 
trials involving thousands of patients at high risk for LC, evaluating the accuracy 
of screening for CTCs have not been possible. As an example, a large prospective 
multi-institutional study was performed using filtration of blood samples (ISET) 
to detect CTCs in COPD patients at high risk to develop lung cancer [29, 30]. 
Unfortunately, this study failed to confirm the initial promise of accurate early LC 
detection, due to difficulties in scaling up such technologies at multiple different 
sites [30]. Therefore, there is an urgent need for the establishment of platforms that 
can isolate CTCs from patients with early LC that are capable of producing reliable 
and reproducible results that are comparable amongst different populations.
Second, LB may be used as a minimally invasive, fairly rapid way, to obtain 
information on actionable mutations in order to deliver targeted therapies, espe-
cially in the case of advanced malignancy, where obtaining a tissue biopsy would be 
difficult. For advanced stage NSCLC, international guidelines have been developed 
by different pathology, molecular and oncology organizations, including amongst 
others the International Association for the Study of Lung Cancer (IASLC) and the 
Association for Molecular Pathology (AMP), the National Comprehensive Cancer 
Network (NCCN) and ASCO regarding a minimum panel of genes that should be 
tested to inform treatment decisions [27].
The recent introduction of comprehensive genomic profiling by NGS using 
ctDNA from LB in patients with advanced stage cancers, including NSCLC, has 
revolutionized the ability of oncologists to treat actionable mutations in this popu-
lation in real time and sequentially, without resorting to invasive tissue biopsies, 
which frequently could not be performed due to lack of tissue or the poor state of 
health of the patient. Thus, in many cases, the convenience and quick turn-around 
time of LB may have significantly prolonged the overall survival of patients in this 
category, who were discovered to have developed actionable mutations follow-
ing first and second -line therapies with conventional chemotherapy regimens or 
biological agents [27, 31].
Third, the ultimate aim or “the holy grail” of LB, is to prescreen at risk popula-
tions for the development of potentially lethal malignancies such as LC, in order to 
monitor these patients and institute rapid treatment if necessary.
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6. Pathogenesis of CTCs
Cancers develop in epithelial cells as a result of chronic exposure to inflammation 
or carcinogens, such as tobacco smoke or air pollution. In the lungs, exposed tissues, 
such as vulnerable epithelial cells in the upper and lower bronchial tracts, may mani-
fest both dysplastic epithelial changes as well as concomitant molecular abnormali-
ties, resulting in a “field -cancerization” effect (Figure 3). In these areas, certain cells 
may undergo unregulated proliferation due to the acquisition of tumor-suppressor 
genes and oncogenes as well as methylation of tumor suppressor genes. Other 
factors, including increased glucose uptake, angiogenesis, an altered tumor micro-
environment (TME) and a cell’s ability to avoid immune surveillance via masking 
of checkpoint inhibitors such as PD-L1, may allow invasion of these genetically and 
phenotypically abnormal cells into the blood stream where they present as circulating 
tumor or CTCs. One of the hallmarks of CTCs is genetic heterogeneity and genomic 
or chromosomal instability (CIN) [33]. CIN includes microsatellite instability (MSI), 
chromosome structural variations such as deletions, duplications and translocations, 
as well as chromosome number. Aneuploidy, due to errors in chromosomal segrega-
tion, is a consequence of CIN and is implicated in tumorigenesis as evidenced by the 
increased rate of malignancies found in patients with global or mosaic aneuploidies. 
The knowledge that aneuploidy is a sine qua non or essential element of a malignant 
cell forms the basis of certain LB tests that rely on the demonstration of aneuploidy 
to detect CTCs or CACs (cytogenetically abnormal cells [24, 25, 33, 34]. Genetic 
mutations arising in CTCs can be characterized by polymerase chain reaction (PCR) 
or next generation sequencing (NGS) on a single cell basis as well as by fluorescence–
in-situ-hybridization (FISH) and immunohistochemistry. [23, 25, 35–37].
Figure 3. 
Left hand panel: A. section of histologically normal ciliated bronchial epithelial cells, overlying 
adenocarcinoma of bronchial origin. B. Microdissection of bronchial epithelial cells adjacent to NSCLC and 
hybridized by FISH showed deletion of gene for surfactant protein a (SP-A) in adjacent bronchial epithelial 
cells, with fewer green signals (SP-A) versus red signals (centromeric 10). C. Tumor cells (white arrow) show 3 
signals of centromeric 10 versus 2 signals of 10q22.3 (SP-A) (green) consistent with deletion of 10q22.3 (SP-A). 
(adapted from Jiang et al. [32]). Right hand panel: Composite diagram of 110 cases of NSCLC demonstrating 
field cancerization effect of left lung following hybridization of lung sections from tumor, bronchus adjacent to 
tumor, proximal bronchus on side of tumor, and normal lung on contralateral side for 3 different DNA FISH 
probes at 3p, and 10q) expressed as percentage deletion. The highest percentages of deletion occur in the main 
tumor mass, however there is evidence of increased deletion of 3p and 10q throughout the lung parenchyma and 
in the proximal ipsilateral main bronchus (shaded areas), compared to the contralateral side. (SPORE grant, 
lung cancer, the University of Texas, M.D. Anderson cancer center).
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Before entering the blood stream, CTCs are required to undergo epithelial 
mesenchymal transition (EMT) in order to traverse the endothelial lining of small 
blood vessels and capillaries [37]. The CTCs have a much larger diameter than the 
diameter of a capillary and need to become deformable. This process requires CTC 
transformation involving micro- RNAs that can interfere with the translation of 
proteins by messenger RNA and facilitate the adhesion of the CTCs to the endothe-
lium and subsequent migration into the blood stream [38]. The number of CTCs are 
extremely rare and are estimated at one CTC per 1x10−6 -10−7. The half- life of CTCs 
in the blood is very short and estimated to be less than 2.5 hours [39].
7. Circulating tumor DNA (ctDNA) and cell free tumor DNA (cfDNA)
Studies have shown that tumor-specific biomarkers exist in the blood. These 
biomarkers represent tumor-derived elements from cancer cells undergoing 
apoptosis and death while traversing the blood stream. These biomarkers include 
circulating tumor DNA (ctDNA) which are fragments of DNA derived from 
Comparison CTCs cfDNA
Origin Intact cells Necrotic apoptotic cells, exosomes
Definition Tumor cells derived from primary
and metastases
Fragmented DNA in circulation, 
includes DNA from normal dying 
cells, ctDNA, cfNucleic acids
Capture and 
Analysis Methods
Enrichment via gradient density, 
immunomagnetic or microfluidic 
based via antigen dependent methods, 
filtration(ISET), CellSearch detection, 
FISH for chromosomal abnormalities or 
translocations and fusions (ALK,ROS1, 
MET)
Enrichment: plasma collection
Detection: PCR- or sequencing based, 
droplet pcr, digital pcr,
Next Generation Sequencing (NGS)
Advantages Extensive downstream analysis (DNA, 
RNA, protein)
Cell culture via capture of viable single 
cells for in vitro or in vivo animal studies; 
NGS sequencing for mutations or copy 
number variations, FDA approved for 
prognosis and detection in stage IV breast, 
Colorectal and prostate cancers, Cell 
Search™ System. OncoDx iFISH for ARv7
Possibility to monitor expression of 
checkpoint inhibitors, PD-L1, PD-1 to 
guide immunotherapy
Slide based methods such as for FISH 
(ref Katz), or IHC (Epic Science) can be 
archived
Easy to isolate from whole blood
Long term storage for subsequent 
analysis
High sensitivity read out
Clinically validated for EGFR 
mutations in NSCLC, comprehensive 
genomic profiling for additional 
genetic mutations (Guardant 
360, Foundation Medicine for 
comprehensive genomic profiling and 
tumor mutation burden (TMB), and 
microsatellite instability).
Disadvantages Low cell numbers
Labor intensive as both detection 
and enrichment steps may require 
highly sensitive and often expensive 
instrumentation
Lack of uniformity of platforms to capture 
CTCs
Not sensitive enough for detection of 
early stage cancers
Limited downstream analysis (DNA 
only) regarding cell culture, PDl1 
assessment




Comparison of circulating tumor cells (CTCs) and cell free DNA (cfDNA).
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malignant cells which reside in a background of cell-free DNA (cfDNA). The DNA 
describes DNA that is freely circulating in the blood stream, but is not necessarily 
of tumor origin; cell free nucleic acid (cfNAs)includes DNA and RNA derived from 
cfDNA, cell free RNA (cfRNA),miRNA and exosomes [25]. Circulating tumor 
DNA fragments (ctDNA) result from activation of nucleases in apoptotic cells and 
increase in response to rapid cell turnover. The burden of ctDNA is proportional to 
the total tumor burden throughout the body as well as the metabolic tumor volume 
as measured by Positron Emission Tomography (PET-CT) [40]. ctDNA is cleared by 
the kidneys, liver and the spleen [41] and is easier to enrich from whole blood than 
CTCs, but until recently, before the advent of NGS for LB, its widespread use was 
limited by the need-to-know which mutations to target by PCR [42]. A comparison 
of CTCs versus ctDNA is presented in Table 1.
8. EGFR mutations detected by LB
In 2016, the U.S. Food and Drug Administration (FDA) approved the first test in 
LB for ctDNA, the Cobas® test (Roche, USA), which was a companion diagnostic 
test for the use of targeted therapy, for detecting the presence of common EGFR 
mutations (exon 19 deletions and the L858R point mutation), which are discov-
ered in up to 16% of Western patients and in 50% of Asian patients with NSCLC 
[28]. The use of tyrosine kinase inhibitors (TKIs) in NSCLC, such as a first line 
TKI, like Erlotinib, is guided by the presence of alterations in EGFR with notably 
better response of patients harboring EGFR exon 19 deletions compared to point 
mutations in EGFR exon 21, whereas patients who have developed the T790M 
mutation after receiving first and second generation TKI’s will have an improved 
PFS response to the third-generation EGFR TKI, Osimertinib. [44]. Resistance to 
TKI’s may be intrinsic or acquired, with the latter occurring as an acquisition of an 
additional genetic mutation to a target therapy such as EGFR or through secondary 
mutations such as gene amplifications in other genes such as Her2neu or MET, or 
changes in tumor histology [28]. Thus, one disadvantage of LB compared to tissue 
biopsy for monitoring advanced disease, is the inability to detect transformation 
of NSCLC to a small cell lung cancer phenotype, which would necessitate dif-
ferent chemotherapy that would include etoposide and a platinum drug such as 
carboplatin or even the addition of an immunotherapy drug such as Atezolizumab 
(Tecentriq) that targets PD-L1 [28].
9. LB for detection of actionable mutations in addition to EGFR
By using a comprehensive multi-genome test panel, as opposed to a single 
targeted PCR test, a LB test may reveal several different mutations that may be ame-
nable to targeted therapies. Serial blood monitoring may in addition, reveal newer 
actionable mutations. The use of NGS to look for actionable genes or biomarkers in 
formalin fixed paraffin embedded tissue sections in cancer patients with advanced 
disease, has been successfully applied in order to institute targeted therapies, 
and has resulted in improved clinical outcomes [45]. However, it has been shown 
that “undergenotyping” or incomplete testing for all guideline recommended 
biomarkers continues to be a challenge in the treatment of patients with metastatic 
NSCLC [27].
Studies have also shown that the results of mutational profiles from LB ctDNA 
in advanced or metastatic NSCLC can be very similar to that obtained in FFPE 
tissue from primary tumor or metastatic sites [27]. A large prospective study 
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of comprehensive ctDNA genotype analysis (Guardant360®) in patients with 
metastatic NSCLC compared to standard-of-care physician requested tissue 
genotyping, demonstrated that guide-line recommended biomarkers were 
significantly more likely to be discovered using the ctDNA LB test compared to 
tissue genotyping [27]. There are eight guideline recommendedbiomarkers and 
include EGFR mutations, ALK fusions, ROS fusions, BRAF V600E mutations, 
RET fusions, MET amplification and MET exon 14 skipping variants, and ERBB2 
(HER2) mutations. There was >98% concordance for FDA –approved therapy 
targets (EGFR, ALK, ROS1, and BRAF) between tissue and cfDNA. In addition, 
there was a faster mean turnaround time in obtaining results of cfDNA compared 
to tissue (9 versus 15 days). Significantly, addition of the LB test in addition to tis-
sue genotyping, increased the detection of actionable mutations, including those 
with negative, or not assessed or insufficient tissue results.
There are differences between the mutational profiles in ever-smoker versus 
never smokers in NSCLC, as well as differences in demographically different 
populations. As an example, 93% of 904 never smokers with lung adenocarcinomas 
in East-Asian populations using surgically resected frozen tumor tissue were shown 
to harbor an actionable mutation that could be exploited as a therapeutic target as 
compared to 31.2% of 1770 patients (779 current or former smokers) with NSCLC 
[46]. In this latter study, comprising 2674 patients, the incidence of METex 14 
skipping was 1.3% in NSCLC and 1.9% in non-smokers with adenocarcinoma. By 
comparison, a NGS LB study of 6,034 Western patients with advanced NSCLC, 
reported METex14 skipping in 3.6% of all patients, demonstrating that this action-
able mutation can be successfully detected by LB, with a genomic profile very 
similar to the aforementioned data obtained on tissue biopsy [47].
In another NGS study a hybrid-capture based 508-gene panel (Oseq-NT) was 
used, that included 119 patients with advanced EGFR –TKI-naïve NSCLC and 15 
EGFR –TKI-resistant patients. In this study, somatic cfDNA mutations by NGS, 
were detected in 82.8% of patients. Actionable genetic mutations were detected 
as 27.7%, predominantly EGFR mutations, including the EGFR T790M mutation 
as well as BRAF mutations, MET mutation and gene fusions for EML4-ALK and 
KIF5B-RET [48]. In August 2020, the first NGS companion diagnostic test, the 
Guardant360® CDx test, that used LB to identify patients with specific types of 
mutations of EGFR in metastatic NSCLC was granted FDA approved [49]. This 
test uses a more sensitive and specific digital sequencing method compared to 
standard NGS assays, in 20 ml of blood, combined with high throughput tumor 
profiling or large panel genetic sequencing to simultaneously detect mutations in 55 
tumor genes.
At the time of this writing, the FDA approval is only valid for targeted therapy 
in relation to EGFR. If other somatic mutations are detected by this EGFR assay, 
patients may then be referred to appropriate clinical trials where suitable targeted 
therapies are being used. There are 73 genes listed on the Guardant Health website 
for point mutations, indels, amplifications and fusions. These include amongst 
other genes, ALK, BRAF, TP53, MET, NOTCH1, EGFR, ERBB2(Her2), CDK6, 
FGFR1, NTRK. For a full description the reader is referred to the website (http://
www.guardanthealth.com/). A second similar test called Foundation One Liquid 
CDx®, (Roche, Switzerland), received expanded approval in late October 2020 by 
the FDA for additional targeted drugs, known as companion diagnostics [50]. This 
test covers single gene alterations in more than 300 cancer -related genes, as well 
as multi-gene signatures such as micro-satellite instability and tumor mutational 
burden (TMB). TMB may be used as a predictive biomarker for delivering immune 
check point inhibitors and refers to the totality of somatic, and coding base substi-
tutions or mutations, and short insertions or deletions per tumor genome, which 
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may result in high numbers of tumor neo-antigens, and increase the likelihood of 
immune recognition by the immune system.
10. Clonal hematopoiesis
The development of somatic mutations in DNA as a result of the aging process 
can affect certain stem cells most commonly in blood and bone marrow, and less 
frequently in other tissues, such as the skin, colon and esophagus. In the blood, 
random somatic mutations in genes (DNMT3A, TET2, and ASXL1) involved in 
epigenetic regulation may confer relative “fitness” on certain hematopoietic stem 
cells, which permits unregulated proliferation of  a process known as clonal hema-
topoiesis (CH). This results in clonal expansion of these cells [51, 52]. CH is highly 
prevalent in the elderly, with between 10 and 20% of individuals over the age of 
seventy, harboring a clone of appreciable size. Because break- down of peripheral 
blood cells, including CH, comprises a large component of cfDNA, CH, which may 
also contain somatic DNA mutations, may be a source of “biological background 
noise” that can lead to false positive plasma genotyping. This has been reported 
in patients with advanced EGFR-mutant NSCLC where mutations in KRAS, JAK2 
V617F and TP53 were detected and confirmed as derived from CH and not tumor 
[53]. To overcome the possibility of false-positive genotyping due to CH in patients 
with NSCLC, paired peripheral blood cell and plasma genotyping may need to be 
performed, so that inappropriate therapy can be avoided.
11. CfDNA for early detection of cancer
In spite of the spectacular success in applying precision therapy via LB to 
patients with advanced NSCLC, in early stage LC, the presence of very low amounts 
of mutated tumor DNA fragments in plasma, makes it difficult to be able to detect 
actionable genetic mutations in the pool of cell-free DNA (cfDNA). In 2019, the 
FDA granted break-through Device Designation to Cancer SEEK™, which was 
developed for early detection of eight common-cancer types, and combines mul-
tiplexed PCR detection of over 1000 mutations identified from numerous cancer 
samples in cfDNA, together with a panel of validated serum protein biomarkers 
[54, 55] including cancer-antigen 125(CA-125), carcinoembryonic antigen (CEA), 
cancer antigen 19–9(CA 19–9), prolactin(PRL), hepatocyte growth factor (HGF), 
osteopontin (OPN), myeloperoxidase (MPO) and tissue inhibitor of metallo-pro-
teinases 1(TIMP-1) The median sensitivity to detect the different types of cancers 
was 70%, ranging from 98% in ovarian cancers to 33% in breast and lung cancers 
[54]. While this assay has very high specificity, it has low sensitivity to detect early 
stage 1 lung and breast cancers. In addition, because the assay is limited in its capac-
ity to determine in which organ the cancer is present, it may be necessary to insti-
tute additional expensive screening tests such as LDCT scan, or other endoscopic 
or ultrasound tests, in order to discover the organ of origin of the cancer [56] which 
may call into question, the actual clinical value and expense of this screening test.
In recent years, large multi-center prospective clinical screening trials involving 
thousands of patients using cfDNA have been conducted, such as the Circulating 
Cell Free Genome Atlas (CCGA) study to determine if genome-wide cfDNA 
sequencing in conjunction with machine learning can accurately detect and deter-
mine the tissue of origin of a large number of cancer types [54] for early cancer 
screening purposes. An off-shoot of this study, whole genome bisulfite screening 
(WGBS) has examined methylation patterns of cell-free DNA fragments using a 
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vast targeted methylation panel based on the The Cancer Genome Atlas (TCGA) in 
a large variety of cancer patients versus non-cancer controls and was able to identify 
with high specificity, but with lower sensitivity, especially for the less advanced 
stage cancers, the presence of cancer as well as the tissue of origin (GRAIL) several 
years in advance of the manifestation of the tumor [55–57]. Studies are in progress 
employing computational biology and machine learning in prospective studies 
in large cohorts of healthy individuals for early detection of clinically actionable 
information from vast amounts of cell free nucleic acids (cfNAs) both DNA and 
RNA, released into the blood stream through high intensity sequencing. The goal is 
to discover unique genetic signatures indicative of early cancer.
12. Composition of blood cells and numbers of CTCs
CTCs are extremely rare events in the peripheral blood stream, with actual 
numbers depending on the platform used to evaluate the numbers of CTCs. For 
example, using a label-dependent method that relied on immuno-magnetic beads 
conjugated to an antibody to EpCAM, (CellSearch®) between 2 CTCs/ml of blood 
for early stage breast cancer, to >5 CTCs/ml of blood, could be detected in patients 
with advanced stage breast cancer [58, 59]. These rare cells are surrounded by up to 
several hundred million lymphocytes and neutrophils per ml of blood. On the other 
hand, using a label-free method to enumerate cytogenetically abnormal cells (CACs) 
by 2-color FISH, patients with NSCLC of all stages had significantly higher numbers 
of CACs than did controls. Depending on the DNA probe used, mean numbers of 
CACs ranged from 7.23 ± 1.32/μl for deletions of surfactant protein A gene at 10q22.3 
to 45.52 ± 7.49/μl for deletions of EIF1B, eukaryotic translation initiation factor, a 
gene located on 3p22.1 [34]. The numbers of CACs detected for patients with NSCLC 
were far higher than the CTCs reported in NSCLC for the Cell Search Instrument 
[34] and could be accounted for by the definition of CACs as a single deletion of a 
genetic probe compared to the internal control DNA probe, as well as the label-free 
method of enumeration, in which all CACs irrespective of immunophenotype, and 
including cancer stem cells, malignant EMT cells and malignant epithelial cells, were 
counted.
In early stage LC, the vast majority of CACs are CK -/CD45- /EpCAM- and may 
express EMT or stem cell markers [25] hence the discrepancy between the FISH 
method and the Cell Search method [34]. In addition to single CTCs, clusters of 
cells may break off from the primary tumor and travel in clusters through the blood 
stream. CTC clusters may form “tumor micro-emboli “(TMI) consisting of up to 50 
cells (Figure 7), that may demonstrate more aggressive properties than single CTCs, 
as they may be surrounded platelets, lymphocytes, neutrophils [60], similar to the cel-
lular components that comprise the microenvironment seen in tumors, which may be 
protect TMI from destruction while circulating in the peripheral blood. TMI together 
with CTCs have also been detected in LB from patients with early breast cancer.
13. Concept of lineage plasticity
For malignant epithelial cells to metastasize, it is postulated that they need to 
adopt an epithelial to mesenchymal transition (EMT) phenotype and undergo lineage 
plasticity by changing their genotypic and phenotypic characteristics. During the shift 
from an epithelial to a mesenchymal state, the adhesion molecules expressed by the cell 
are modified, allowing it to adopt a migratory and invasive behavior. EMT is induced 
by specific transcription factors such as Snail, Zeb and Twist, and miRNA’s which 
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together with epigenetic and post translational regulators, mediate the process of EMT. 
EMT is involved in wound healing, embryogenesis and cancer metastases. Most impor-
tantly, EMT has been shown to trigger the dissociation of cancer cells from the primary 
epithelial tumor mass and enable these cells to disseminate as CTCs into the blood 
stream. In a label- free study of peripheral blood mononuclear cells (PBMCs), it was 
demonstrated by FISH that there were higher numbers of CACs in patients with lung 
cancer and breast cancer across all stages than had previously been reported by other 
methods [25, 59, 61, 62]. This included label-dependent bead-based antibody capture 
systems for EpCAM, in which captured cells, that are CK+/ CD45- and stain for DAPI 
are defined as CTCs [58]. Notably, the FISH assay identified far higher numbers of 
CACs in patients in both early and advanced NSCLC compared to the low numbers 
of CTCs reported by EpCAM immune-antibody-cell capture methods including the 
CTC –chip [63]. It was also demonstrated by IHC for stem cell markers (ALDH1), 
mesenchymal markers (SNAIL) and CK combined with FISH, using a method 
known as FICTION, [64] that the CACs that were previously identified based solely 
on genetic abnormalities [34] actually represented diverse cohorts of pluri-potential 
CTCs including malignant stem cells and cells which had undergone EMT with loss of 
epithelial markers [25]. Further evidence for lineage plasticity and phenotypic switch-
ing was obtained by serial monitoring of blood for CTCs both before, and at several 
time points after, resection of LC [25]. In early stage LC the vast majority of CACs are 
negative for epithelial and lymphoid markers (CK-/CD45-), most likely representing 
EMT cells and stem cells. At later time points or as LC becomes more advanced, more 
CACs that are CD45+/CK+ or CK+/ CD45- are identified [25]. The not infrequent 
finding of genetically abnormal circulating cells co-expressing CD45+/CK+, or CK 
-/CD45- contradicts the classic definition of a CTC as defined by the FDA approved 
CellSearch® test [58]. This observation may account for the higher sensitivity of an 
antigen-independent gene-based test. It has also been shown that only a minority of 
CTCs with stem cell properties are able to survive and initiate metastases [65].
Figures 4 and 5 depict a 43-year-old patient with stage IB, poorly differentiated 
squamous carcinoma, showed CACs of all lineages(lineage plasticity). a CD45–/
CK+ cell showing 3 red (10q22.3) and 3 green (Cep10) signals. b CD45+/CK– cell 
with 2 green (Cep10) and 3 red (10q22.3) signals. c CD45–/ALDH1+ stem cell with 
Figure 4. 
Demonstrating lineage plasticity in CACs (by combined immunofluorescence and FISH (FICTION)).
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2 red (10q22.3) and 1 green (Cep10) signal. d CD45+/CK– cell with 2 red (10q22.3) 
and 1 green (Cep10) signal. e CD45–/CK+ cell with 2 red (10q22.3) and 1 green 
(Cep10) signal. f  EMT cell with 2 red (10q22.3) and 1 green (Cep10) signal. White 
arrows indicate the location of FISH signals [25]. Figure 5 is derived from the same 
patient and demonstrates CACs from baseline before surgery to 6 months following 
surgery, with a return of CACs to baseline, following a peak in CACs observed at 2 
months post surgery (Figures 4).
The significance of the EMT phenotype in initiating metastases was demon-
strated by studies of CTC derived xenografts (CDX) from patients with advanced 
NSCLC, which demonstrated a mesenchymal phenotype [28, 66].
14. Methods for isolation of CTCs from blood
Different platforms have been developed to isolate CTCs. These can be divided 
into affinity, label or antigen dependent methods or affinity- or antigen-indepen-
dent or label-free methods (Figure 6).
Affinity or label dependent devices include the CellSearch® System and the Mag 
–sweeper, as well as the CTC chip, because all rely on magnetic particles, beads, 
or posts, coated with antibodies to EpCAM that capture CTCs secondary to the 
expression of EpCAM on their surface membranes (Figure 6a,b).
Label free methods can isolate CTCs based on their physical properties and include:
a. CTC separation via density gradient centrifugation, which enables enrichment 
of CTCs [67] followed by fluorescence in situ hybridization (FISH) to identify 
cytogenetically abnormal cells (Sanmed Multiplex 4 color FISH test)  
(Figure 6e) [24] or immunocytochemistry for different biomarkers expressed 
on cancer cells such as Her2neu, estrogen receptors (ER) or cytokeratin’s.
Figure 5. 
Histogram of CACs from the same patient as in Figure 4. FICTION method for CD45 and CK, combined 
with DNA probes for Cep3/3p22.1, Cep10/10q22.3, UroVysion Cep3,7,17, 9p21.3, and LAVysion, EGFR, TERT, 
C-MYC, and Cep6,showed increase of double-negative CTCs at 2 months in Cep3/3p22.1 abnormal cells and 
increase of CD45+/CK–CTCs in Cep10/10q22.3 abnormal cells, and increase of all CTC lineages in EGFR, 
C-MYC, and Cep6 abnormal cells at 2 months, followed by a marked decrease in all CTCs at 6 months [25]. 
Note that “CAC peaks” as shown in 3/4 of the above diagrams,occurred at two months post surgery, and 
returned to baseline at 6 months in patients with a good prognosis.
Histopathology and Liquid Biopsy
14
b. Microfluidic devices that use physical properties of the larger less deformable 
CTCs that allows inertial focusing to detect CTCs (Vortex Clear Cell FX™) 
(Figure 6c) and include a micro cavity array system that traps CTCs into 
10,000 cavities arranged in a 100x100 array with each cavity fabricated to have 
a diameter of 8–9 μm [68].
c. A microfluidic device that traps cells (Parsortix™ Cell Trap)  
(Figure 6d) [1].
d. Various filtration devices that use membranes or screens with small pores that 
allow the WBCs to flow through but trap single CTCs and clusters of CTCs 
based on the larger size of the CTCs on the surface (Cell Sieve, ISET™, Screen 
Cell™Cyto) (Figure 6f) [1].
e. Imaging methods that promote total tumor cells capture by minimal sample 
manipulation examining all nucleated cells in the blood by immunofluores-
cence (IF) for different antigens and tumor markers such as CK, ER, AR, Her2, 
or CD45 or FISH for aneuploidy and high-definition imaging for cell morphol-
ogy (such as the EPIC™ test or Tethis SBS Platform) (Figure 6g) [1, 69, 70].
15. Antigen dependent devices or methods
15.1 Immunomagnetic devices
The CellSearch® (Menarini-Silicon Biosystems, San Diego, CA) method 
relies on ferrofluid based immunomagnetic separation of EpCAM expression 
to isolate epithelial cells [58, 59, 71] which are confirmed as CTCs by staining 
Figure 6. 
Diagram depicting methods for isolation and detection of CTCs using either a) affinity –dependent detection 
devices usually employing magnetic particles, beads or posts coated with EpCAM such as a) CellSearch®, 
MACS or mag-sweeper or b) CTC chip or B) affinity-free detection devices relying on physical properties of 
CTCs such as larger size or deformability compared to other blood cells using c) inertial focusing or d) trapping 
of cells when passed through a Parasortix® filtration cassette or e) enriched on a Ficoll–Hypaque gradient 
due to specific gravity and centrifugal forces and characterized based on genetic abnormalities by FISH such as 
the Sanmed™ multiplex 4-color FISH test or f) trapped on filtration membranes that only permit passage of 
white blood cells with a pore size smaller than CTCs such as cell-sieve, ISET™, screen cell™ Cyto and g) total 
cell capture coupled with red blood cell lysis and immunocytochemistry or FISH together with high resolution 
imaging for cell morphology for detection of CTCs, such as the Epic or Tethis SBS platforms.
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positive for high expression of cytokeratin’s CK8, 18 and 19, and absence of expres-
sion of CD45, a lymphoid marker. Thereafter the cell, is stained with DAPI (4, 
6-diaminidino-2-phenylidole) a nuclear stain. The requirements tor this test are 
7.5 ml of whole blood, collected in special CellSave tubes (Figure 1). Most CTCs 
will go through epithelial–mesenchymal transition (EMT) when they extravasate 
into the bloodstream, resulting in a loss or down regulation of EpCAM expression 
and are therefore poorly detected by this isolation method [60, 62, 71]. Loss of 
EpCAM is particularly notable in early stage NSCLC. In spite of the loss of epithelial 
marker expression in the CTC population, CellSearch® is the only CTC test that 
was approved in 2004 by the US Food & Drug Administration for clinical use for 
patients with metastatic breast, colorectal and prostate cancer, as well as prediction 
of survival in advanced NSCLC [58]. Since then, this test has been used in many 
studies with reliable and reproducible results [72–74]. CellSearch® has shown 
prognostic significance in detecting CTCs in most breast cancer subtypes, with a 
cut-off of ≤2 being a marker for long time survival [75] while ≥5 CTCs was associ-
ated with a decrease in 5 year survival. This device in its conventional set up, has 
drawbacks regarding sensitivity for capturing the whole dynamic range of plasticity 
that CTCs may demonstrate as it may not detect many cells that have lost or down 
regulated their EpCAM expression. Thus, numerous studies of solid tumors have 
reported zero or only 1–2 CTCs that can be recovered by the Cell Search instrument 
as currently configured [59, 71]. There are also certain solid tumors such as NSCLC, 
pancreatic cancer and triple –negative breast cancer, where the predominant 
component of CTCs are of the EMT type and hence, would not be detected by 
CellSearch® [25, 59].
15.2 Microfluidic chips
Microfluidic chips allow for cells to be captured, immobilized and then washed 
out, after which they can be subjected to molecular assays. Blood flows through 
78,000 micro posts placed at very narrow intervals, forcing cells to move along nar-
row channels and enhancing their opportunities for contact with posts coated with 
EpCAM (Figure 6b), thus CTCs expressing EpCAM, become immobilized and 
attach to the walls of the chip resulting in the negative depletion of white blood cells 
(WBCs) which lack expression of EpCAM. Other chips may use antibodies such as 
anti-CD45 or anti CD66 for negative depletion resulting in retention of WBCs and 
elution of CTCs. The advantages of the CTC-chip compared to the CellSearch® 
instrument is the higher yield of CTC capture (median 50 CTCs per milliliter), 
as well as on-chip lysis which permits extraction of DNA and RNA for molecular 
analysis [63].
15.3 Bead based subtraction-enrichment strategies
Positive immunomagnetic bead-based CTC enrichment methods may rely on 
epithelial antigens such as EpCAM for capture and/or intra-cellular tumor cell 
antigens such as cytokeratin for detection, however, CTCs undergoing epithelial-
mesenchymal transition, may be missed [76–79]. To avoid this failure, negative 
selection approaches exist for unbiased CTC enrichment [80]. Negative immuno-
magnetic selection uses a cocktail of antibodies against hematopoietic antigens such 
as CD2, CD14, CD16, CD19, CD45, CD61, CD66b and Glycophorin A, to enrich for 
CTCs, by removing contaminating white blood cells and platelets. An example of 
such an assay is the RosetteSep™ (STEMCELL Technologies). Antibody labeled 
WBCs can also be removed by AutoMACS Separator (Miltenyi Biotec). A major 
disadvantage of negative selection approaches is the lower CTC purity as compared 
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to the positive selection approaches; however negative selection approaches show 
promise for identifying more CTCs for downstream analyses. Both epithelial and 
mesenchymal cancer cells could be enriched from patient samples [76, 79–81].
15.4 Magsweeper
MagSweeper technology is an automated immunomagnetic cell separator that 
uses a magnetic arm to collect cells coated with anti-EpCAM antibodies [79]. This 
EpCAM based isolation method can capture high-purity cells from metastatic 
cancer patients, but adsorption of background cells to the capturing device or the 
entrapment within the large magnetic particles used for labeling rare cells in large 
volume could lead to nonspecific contamination. However, MagSweeper is not 
commercially available, which might require further analysis to validate the effec-
tiveness of the test [83].
15.5 CellCollector
The CellCollector is a modification of a medical device for use in vivo. It uses 
a wire with an antibody against EpCAM that is attached to the surface and is 
inserted through a cannula straight into patients’ bloodstream and left exposed to 
a high volume of blood for 30 minutes to collect CTCs  [84]. This device has been 
used successfully  ex vivo to quantitate the number of CTCs in 15ml of blood from 
patients with prostate cancer [85]. In spite of the complicated in vivo application 
procedure, Luecke et al. [86] reported that the CellCollector can capture a higher 
volume of CTCs compared with the CellSearch method (73% vs. 29%) in 62 lung 
cancer patients. Further studies with larger samples will be required to demonstrate 
the efficiency of this technology.
16. Antigen independent platforms
16.1 Enrichment free platforms or “No Cell Left Behind”
Following red cell lysis of a whole blood sample, CTCs are captured by 
analyzing all nucleated cells present so that the final result is fully representa-
tive of the entire cell population in the blood sample except for the red blood 
cells. (Epic Science, San Diego, CA) [69, 87]. This test attempts to identify CTCs 
defined as: a) CK+/CD45- with abnormal morphology; b) CK - /CD45- with 
abnormal morphology, which may be cancer stem cells or cells undergoing EMT; 
c) Apoptotic CTCs, which are the abnormal cells described in a and b, but with 
nuclear fragmentation and d) CTC clusters, 2 or more individual cells bound 
together. Cells are stained with a cocktail of cytokeratin, CD45 and DAPI and 
then analyzed at high resolution by digital pathology methods for numerous 
nuclear, nucleolar and cytoplasmic features. Machine learning algorithms then 
quantify CTC subtypes into different categories. Cells of interest are confirmed 
by a trained operator as to whether they represent CTCs. This platform is also 
used for nuclear localization of AR-V7 in CTCs from patients with metastatic 
prostate cancer, which if positive, is indicative of resistance to androgen –tar-
geted therapy, suggesting alternative therapies such as chemotherapy or other 
therapies [87].
A similar approach has been used for detection of CTCs and in early breast can-
cer using of IF for estrogen receptors and CK/and or Her2 and morphology in bright 
field. In combination with proprietary slides to enhance cell retention (Tethis, 
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Milan, Italy), this method allows gently and quick white blood cell adhesion as a 
monolayer with no selection, avoiding shear stress or manipulation associated with 
enrichment methods and thereafter examining the whole repertoire of nucleated 
cells [69] (Figure 7) thus leaving the architecture of CTCs in the peripheral blood 
intact. This method, which has been automated and standardized in its pre-analyti-
cal phase of sample preparation on slides, has shown high sensitivity and specificity 
in single CTCs and also CTCs cluster detection in a pilot study of early breast cancer 
[69]: identification of CTC clusters in early breast cancer is a novel finding that will 
deserve further confirmation in larger clinical trials. The presence of CTC clusters 
in metastatic settings has been clearly associated with a more aggressive tumor 
phenotype [70]: identification of such biomarkers in early settings could open 
new perspectives for the evaluation of their prognostic relevance and consequent 
therapeutic decision in early breast cancer.
16.2 Fluorescence-in-situ hybridization or FISH-based assays
A novel way to look at the genotype of individual cells is to perform interphase 
FISH (iFISH) using DNA probes that may be localized to locus specific, centro-
meric or telomeric sites on the chromosomes. iFISH can identify if cells are diploid 
(normal) or aneuploid (malignant) based on the gains and/or loss of chromosomes. 
Panels of probes may be custom made and designed specifically to detect certain 
types of cancers, such as the Sanmed ™ test for LC, in which cDNA subtraction 
hybridization using DNA extracted from resected NSCLC specimens versus normal 
lung tissue was used to discover universally deleted genes [88]. The latest automated 
fluorescence technology using pseudo -confocal microscopy, permits up to 6 different 
DNA probes to be quantitated simultaneously in a single nucleus using different color 
fluorescent tags [89] thus allowing an opportunity for up to 6 different genetic mark-
ers to be analyzed on a per cell basis (Bioview, Rehovoth, Is.) and creating opportuni-
ties to devise novel biomarkers customized to different subtypes of cancers.
To maximize the enumeration of CTCs by FISH, a gradient centrifugation 
process is used, which causes the neutrophils and RBCs to precipitate at the bottom 
of the tube, while cells with abundant cytoplasm, such as CTCs, peripheral blood 
mononuclear cells (PBMCs) including monocytes and lymphocytes, band at the 
buffy coat due to the effect of specific gravity [24, 25, 67] (Figure 8). For chromo-
somal abnormality enumeration, thousands of purified cells from the buffy coat 
are subjected to iFISH, with multiple DNA probes labeled with different fluorescent 
tags [24] in order to identify nuclei containing gains or polysomies, and/or deletions 
of different targeted genes. These cells are also known as cytogenetically abnormal 
cells or CACs. Preparations are scanned on an automated fluorescent microscope 
Figure 7. 
CTC clusters in early breast cancer (a) 40x magnification of a CTC cluster stained with DAPI, and 
immunostained with CK and CD45, and stained with Papanicolau; (b) bright field analysis of a whole slide 
showing different CTC clusters (Papanicolau staining).
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with multiple filter wheels of different wavelengths to detect different color signals 
(e.g., Bioview Duet Instrument Rehovoth™, Il). This instrument can be pro-
grammed to count cells of a certain size and to exclude cells the size of a lymphocyte 
or smaller cells. At the end of each scan, a pie chart is produced, according to a pre-
determined classification of signals. Digitization of cells subjected to FISH, can be 
performed fairly rapidly, however manual evaluation by a qualified technologist, of 
genetically abnormal cells, is mandatory, but can be time-consuming. Using strict 
criteria, only cells with intact nuclei that demonstrate good hybridization signals of 
all probes are analyzed (Figure 8).
In a 4-color FISH test such as the Sanmed™ test, the goal of the analysis is to 
find unequivocal aneuploid CTCs as defined by polysomy of 2 or > signals of dif-
ferent nucleic acid probes per nucleus. This criterion is the same one that is recom-
mended for a similar 4-color FISH test, the Urovysion™ FISH test (Vysis, Abbott 
Labs, Chicago, Il) for the diagnosis of urothelial carcinoma in urine specimens in 
patients to rule out bladder cancer [91]. A threshold for calling a specimen positive 
or negative is established based on the lowest number of CTCs present in cancer 
patients with histologically confirmed primary cancers as compared to the highest 
number of CTCs present in a matched control population. The optimal threshold is 
the one that most accurately predicts the presence of cancer [24].
Recently, Katz et al. [24] used a 4-color FISH assay to evaluate cytogenetic 
abnormalities of 3p22.1 and 10q22.3 in 207 patients, including 100 control subjects, 
who were at risk of developing NSCLC, based on risk factors for LC as well as 
suspicious LDCT findings, using ≥3 CTCs as a threshold for malignancy, and suc-
cessfully identified patients at stage I and II NSCLC with a high degree of accuracy 
(Figure 9, Table 2).
CTCs were identified as a complete cell with a nucleus larger than a lympho-
cyte nucleus that contained polysomy of at least 2 of 4 FISH probes per nucleus. 
Strikingly, the accuracy of this method to detect early-stage LC was significantly 
higher than other published EpCAM based technologies, most likely due to the 
high sensitivity of the 4-color probe cocktail that is used to detect cytogenetically 
abnormal circulating cells and is not dependent on EpCAM expression [24, 71, 95].
An environmental study that employed the 4-color FISH assay showed an 
89.47% sensitivity and an 85.00% specificity to detect LC in 89 Chinese bus drivers 
who had indeterminate lung nodules on LDCT following chronic and consistent 
exposure to occupational pollutants [92]. Similarly, Liu et al. in a prospective 
Figure 8. 
The workflow of CAC enumeration, from left to right, collection of 10 ml of peripheral blood, enrichment of 
peripheral blood mononuclear cells, hybridization of FISH probes, fluorescence image acquisition and analysis 
followed by cloud based data review and report [90].
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case–control study involving 339 participants, indicated that the 4 color FISH test 
yielded 67.2 sensitivity% and 80.8% specificity in stage I NSCLC patients, including 
those with solid nodules (38.7%), mixed ground-glass nodules (mGGn) (31.9%) 
Figure 9. 
High degree of sensitivity and specificity demonstrated in 3 separate cohorts comprising patients with 
predominantly early stage cancer and controls using a threshold of ≥3 CTCs to determine the presence of 
malignancy, A) discovery cohort, first 118 B) validation cohort, subsequent 89 and C) overall cohort, 207 
patients (107 patients and 100 controls) [24].
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n = 89
Non-specific Stage I 89.47% 85% [92]













Chinese, n = 125 5–10 
millimeters
StageI 70.4% 86.4% [93]


















Abbreviations: mGGNs, mixed ground glass nodules, pGGNs, mixed ground-glass nodules.
Table 2. 
Performance of 4 color FISH test in LDCT detected lung nodules for identification of lung cancer in different 
populations [24, 90, 92–94].
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and pure ground-glass nodules (pGGn) (28.4%) [90] detected by LDCT. In addi-
tion, in this study the discriminatory capability between CACs and traditional 
tumor serum biomarkers such as CEA, TPSA, NSE, CA19–9 and CYFRA21-1 was 
compared to the results of the 4 color FISH assay and showed that the sensitivity of 
the CAC assay was significantly higher for small nodules and ground glass nodules 
when compared to the serum biomarkers [90].
In a different study, 125 individuals with newly discovered pulmonary nodules 
5–10 millimeters in diameter by LDCT, underwent LB for the 4 color FISH test 
prior to surgery, followed by histopathological examination of the resected nodules. 
Here, in spite of the extremely small size of the nodules, the FISH test demonstrated 
a 70.4% sensitivity and an 86.4% specificity for the diagnosis of LC [93]. The 
advantages of using this assay were demonstrated in yet another study that collected 
lung LDCT images of 534 patients with pulmonary nodules and invited experienced 
physician to score the patients’ lung cancer risk and to compare the risk score to that 
Figure 10. 
(a) Overview of proposed clinical study to test robustness of AI assisted LDCT of lung nodules combined with 
evaluation of Sanmed test by AI in order to evaluate whether a pulmonary nodule is low, intermediate or high 
risk for cancer, with follow up recommendations. (b) Overview of AI based tools, include nodule segmentation, 
feature extraction, modeling and prediction based on established radiology guidelines, such as lung-RADS and 
the Fleischner society, in order to improve and standardize interpretation of lung nodules. Bueno et al. [96].
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calculated by Artificial Intelligence with deep learning. In all 11 cases where both 
physicians and AI incorrectly predicted the lung cancer risk factor, the results of the 
4- color FISH test was consistent with the results of the histopathological examina-
tions [94]. When LDCT image analysis is insufficient to make a clinical decision, 
the 4 -color FISH test may be a valuable complementary tool for individuals with 
indeterminate LDCT results.
Based on initial studies, it appears that the multiplex–FISH LB assay is robust 
and has the potential to be scaled up for widespread use. Reproducible results with 
an acceptable degree of clinical utility were obtained on numerous blood samples 
from different geographic locations, in which pre-analytical values were kept con-
stant, regarding the volume of blood (10 mL collected in K2EDTA vacuum tubes), 
as well as methods of fixation and stabilization of blood samples for up to 96 hours 
at room temperature, before being processed in a centralized certified laboratory 
according to standard operating procedures. The multiplex- FISH CTC assay is 
currently being tested in a prospective study comprising large cohorts of at-risk 
subjects, in combination with computerized scanning of LDCT detected indetermi-
nate lung nodules in order to confirm that the FISH assay, in conjunction with the 
artificial intelligence (AI) interpretation of the lung nodule may have an important 
and synergistic role to play in early LC detection (Figure 10a and b).
16.3 FISH quantitation by artificial intelligence (AI)
A drawback of the different FISH assays has been the length of time taken to 
manually evaluate and accurately enumerate fluorescent signals due to overlap-
ping cells and/or other technical difficulties such as splitting of signals, resulting in 
inaccurate counting and overcalling of CTCs and distinguishing CTCs from debris 
and leukocytes [94, 97]. However, the development of machine learning algorithms 
in implementing the CTC counting procedure has been able to make the process 
far more efficient and accurate. Machine learning(ML) algorithms that function 
in advancing cell image analysis can automatically input layers with a geometric 
relationship, as well as precisely capture the rows and columns of images; thus 
ML can rapidly recognize CTCs with extra intra-nuclear structures compared to 
normal cells, in order to reduce the artificial errors and improve the precision of 
Figure 11. 
Diagram of instrumentation (De novo®, BioView, Rehovoth, is) currently in use (left hand panel) 
for automated imaging comprising 3D image capture, cell segmentation, exposure adjustment and cell 
classification. Right hand panel depicts deep learning algorithms to improve classification of cells including cell 
segmentation, signal detection and CAC identification and characterization.
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Figure 12. 
Filter preparation, screen cell, of CTCs derived from a patient with stage IV adenocarcinoma of lung showing 
numerous CTCs, both single and in clusters a) diff- Quik 20X b) diff -Quik 40X, c) same patient, clusters of 
adenocarcinoma, morphologically resembling CTCs, in pleural fluid, hematoxylin and eosin 10X, d) 40X, e)
CTCs multiplex 4 color FISH (3, 3p, 10, 10q) demonstrating aneuploidy 400X, f) EML-ALK translocation, 
CTCs X400, g)pleural fluid X400, h) multiplex 4 color FISH (3, 3p, 10, 10q), pleural fluid X600.
CTC identification [98, 99]. For example, the BioView platform automates image 
collection and is able to utilize an algorithm for identifying CTCs according to cell 
size, cell shape, nucleus to cytoplasm ratios, and occurrence of biomarkers identified 
by target features, and can automatically select CTCS from other cells in peripheral 
blood in a timely manner and has been widely applied in many FISH based CTC 
enrichment processes [100, 101] (Figure 11). In another AI study involving analy-
sis of the 4-color FISH LB assay, FISH probes were segmented using 3D-Unets, 
which enabled a significant reduction in false –positive enumeration of polysomies 
obtained during traditional computer vision microscopy, while retaining all verified 
CTCs, greatly improving the efficiency of the scoring pathologists and the accuracy 
of the test [102].
16.4 Filtration methods
16.4.1 Filtration devices
CTCs may be isolated by the size of epithelial cells (ISET) (Rarecells 
Diagnostics, Paris, France) [103, 104] via a blood filtration approach which 
enriches 10 ml of peripheral blood collected in buffered EDTA and kept at room 
temperature. The membrane used is made of polycarbonate and allows cells <8 
microns to pass through, while the larger epithelial and mononuclear white blood 
cells remain on top (Figure 6f). Half of the membrane can be used for morphol-
ogy via a May Grunewald Giemsa stain, and the second half can be used for 
immunocytochemistry using a pan-cytokeratin antibody and an anti-vimentin 
antibody applied to the filters. Malignant cells are identified cytologically accord-
ing to usual characteristic nuclear and cytoplasmic features. Another similar 
platform is the CellSieve method that uses microfilters and a pressure monitored 
filtration pump from Creative MicroTech, Inc., Rockville, MD (Figure 12). 
Another filtration device similar to that has enhanced cell recovery for in vivo 
quantitation of rare CTCs via multiphoton intravital flow cytometry [105]. 
Successful size- based isolation of CTCs has been described using a microcavity 
array system that traps CTCs into 10,000 cavities arranged in a 100x100 array 
with each cavity fabricated to have a diameter of 8–9 μm [68]. This method 
was shown to be superior to CellSearch in detecting CTCs from patients with 
NSCLC and small cell lung cancer. Filtration devices have been successfully and 
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extensively used [103], to detect CTCs, both for screening for lung cancer in 
high risk COPD patients, as well as in patients with established diagnosis of LC 
[71]. In a large study of patients with and without COPD, investigators noted 
that 5/168 patients with COPD or 3%, all of whom had negative spiral CT scans, 
manifested CTCs one to 4 years before the appearance of indeterminate lung 
nodules. All nodules proved to be early stage lung cancer on surgical resection 
[104]. The CTCs were isolated by the ISET filtration method and were stained 
with both epithelial and mesenchymal markers. In a side-by-side comparison of 
40 patients with advanced NSCLC, predominantly stage IV, using the filtration-
based size exclusion technology ISET (Rarecell Diagnostics), investigators 
detected higher numbers of CTCs including epithelial marker- negative cells in 
32/40 or 80% of patients as compared to CellSearch where only 9/40 or 23% of 
patients were found to have CTCs In addition circulating tumor microemboli 
(CTM) were detected by filtration but were not detectable by CellSearch [71]. 
Immunohistochemistry stains on cells isolated by ISET showed variable expres-
sion of EGFR, CK and Ki67, however EpCAM expression was not detected. 
Despite the initial promising results of ISET capability for identifying high risk 
individuals that could develop LC, in a recent multicenter study, CTC detection 
using ISET was shown not to be suitable for lung cancer screening. In this study, 
factors limiting the widespread use of ISET for screening for LC, included pre-
analytical factors, such as use of different blood collection tubes such as EDTA 
(ethylenediaminetetra-acetic acid) or Streck BCT (Streck, Omaha Nebraska) 
tubes, and imprecise standardization of the filtration method, by different 
operators [30]. It was subsequently concluded that in order to define a robust 
CTC test, suitable for real world consumption, large multi-center trials with 
large numbers of patients, using uniform pre-analytical conditions and identical 
technical analysis is essential [30].
One notable disadvantage of the filtration methods is that there exist subpopula-
tions of CTCs whose size is smaller or in the same size range as WBCs (around 5 
microns) and therefore would be eliminated during the filtration process. This 
feature may contribute to a lower sensitivity of CTC detection compared to other 
methods for enrichment of CTCs that do not rely on filtration [81].
Figure 13. 
Left hand panel, showing ALK gene rearrangements (white arrows) in H2228 lung cancer cell line, Vysis ALK 
break apart FISH probe kit (Abbott, molecular diagnostics, Des Plaines, IL). Right hand panel showing CTCs 
demonstrating ALK break apart gene rearrangements (white arrow) in CTC and normal cells with fusion signal 
seen as closely opposed green and red signals (yellow arrows), BioView duet™, scanning system, Rehovot, is.
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16.5 Specific chromosomal abnormalities to detect CTCs
A method known as FICTION which combines IFISH and IHC may be used 
to simultaneously analyze the genotype and phenotype of a single CTC and can 
be used to study phenotypic and genotypic changes in the same cell [25, 64] The 
anaplastic lymphoma kinase (ALK) fusion gene is a driver gene for non-small 
cell lung cancer (NSCLC) [106]. ALK-positive NSCLC has been considered as a 
molecular subtype of NSCLC that provides unique clinicopathological charac-
teristics of cancer diagnosis and prognosis [106, 107]. Initially, researchers found 
Figure 14. 
(A) Multiplex fast FISH assay for detecting ROS1, RET and MET aberrations in FFPE non-small cell lung 
cancer specimens using BioView Duet™ scanning system for automated slide imaging and digital analysis of 
6-color probe assay. Examples of case reports and representative images of cells positive for RET, ROS1 and 
MET aberration a) RET break apart probes labeled with Spectrum Green (5′ RET Cen) and Spectrum Red 
(3′ RET Tel) and captured with corresponding filters. b) ROS1 break apart probes labeled with SpectrumAqua 
(3’ ROS1 Cen) and SpectrumGold (5’ ROS1 Tel, pseudocolored in Orange) and captured with appropriate 
filters rearrangement probe. c) MET gene copy number probe labeled with Alexa 647 (pseudocolored in 
Magenta) and centromeric probe CEP7 labeled with Alexa 750 (Blue) and captured with appropriate filters. 
d) Combined image of the multiplex FISH assay with probe mix contained 6 differentially labeled fluorescent 
probes: 3’ ROS1, 5’ ROS1, 3′ RET, 5′ RET, MET and CEP7. (B) Figures supplied courtesy of Dr. Irina Sokolova, 
Tatyana Grushko and Katerina Pestova, Abbott, Molecular Diagnostics, Des Plains, IL [89].
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that the EML4-ALK fusion gene exists in NSCLC patients by PCR and proteomics 
methods. However, due to the variation of fusion partners of ALK fusion genes, 
as well as the possibilities of unknown fusion partners, the FISH method with 
specific probes is an accepted and essential FDA approved companion diagnostic 
method performed on FFPE sections of NSCLC [108]. Currently, FISH has been 
considered as the gold standard of detecting ALK rearrangements [107, 109] 
using the Abbot Vysis ALK Break Apart FISH Probe Kit. The kit is designed with 
the 3′ and 5′ probes labeled by red and green signals; once abnormalities of ALK 
have occurred, deletion or splitting of the signals will be detected [110]. The 
limitation of the FISH based ALK test includes high cost and the utilization of 
specialized equipment [110, 111]. Studies have demonstrated CTCs containing 
the ALK-EMLK1 gene rearrangements in patients with NSCLC [108–112] (see 
Figure 13) as well as in ex vivo cultures of CTCs from patients with NSCLC [113].
An enriched cell preparation can be used to detect oncogene fusions due to chro-
mosomal translocations or inversions in lung cancer such as ALK-EML1, ROS-1 or 
amplifications of oncogenes such as Her2neu or EGFR. Recently a novel FISH assay 
was described that can simultaneously detect ROS1, RET, and MET chromosomal 
aberrations in cells of NSCLC on FFPE tissue. This assay has the potential to be used 
on CTCs [89] (Figure 14a–d).
17. PDL-1/PD-1 on CTCs
In recent years the development of tumor immunotherapy drugs, especially 
immune checkpoint inhibitors (ICIs) targeting the programmed death pro-
tein (PD-1)/ programmed death ligand 1(PD-L1) has changed the paradigm 
in the treatment of malignant tumors and has shown superiority in terms of 
therapeutic effect and quality of life compared with traditional chemotherapy 
Figure 15. 
Top panel: Example of metastatic adenocarcinoma of lung in pleural fluid in a patient with advanced 
lung cancer, A) papillary and acinar fragments of adenocarcinoma (H&EX20); B) PD/L1 IHC clone 
22c3(pharm dx, Dako, CA) showed weak membranous expression, overall score < 50%; C) ALK IHC, clone 
D5F3 showed strong expression consistent with a positive test. Bottom panel: D) squamous carcinoma lung, 
moderately differentiated, transbronchial biopsy, H&E X40, E) and F) PD/L1 IHC22C3 shows strong positive 
membranous staining in >90% of malignant cells, G) Alk IHC, clone D5F3, showed negative expression 
consistent with a negative result.
Histopathology and Liquid Biopsy
26
[114–118]. Single-agent immune checkpoint inhibitors are now standard of care 
for advanced non-small cell lung cancer (NSCLC), and emerging data show 
that combining these agents with established chemotherapy further improves 
progression free survival and overall survival. The Phase III KEYNOTE-189 and 
IMPower-130 trial showed significantly improved survival using this strategy 
for non-squamous NSCLC, and the phase III KEYNOTE-407 trial showed similar 
results in squamous disease [119].
PD-L1 is a type 1 transmembrane protein with an extra-cellular N-terminal 
domain which inhibits or blocks the immune response by interacting with the 
PD-1 receptor which is expressed on activated T- and B-cells, and macrophages. 
Anti-PD-L1/PD-1 antibodies can reactive the immune system to eradicate tumors 
by blocking checkpoint proteins from binding with their partner proteins. PD-L1 
expression may inform the use of checkpoint inhibitor combination therapy, 
while overall tumor mutation burden is also an emerging biomarker for ICIs. 
Antibodies that have FDA approval for NSCLC are two that block PD-1, namely 
Nivolumab (Opdivo, Bristol-Myers Squibb) approved for third line approval 
and Pembrolizumab (Keytruda, MSD SHARP and DOHME GMBH), which has 
approval for first- and second line-treatment, and one antibody blocking PD-L1, 
namely Atezolizumab (Tecentriq, Roche) for third line–treatment settings.
Immunohistochemistry (IHC) on tumor tissue, using the recommended FDA 
approved IHC-companion diagnostic for PD-L1, Ventana PD-L1 SP142 assay 
(Ventana Medical Systems, Tucson, AZ, USA) and PD-L1 IHC 22C3 PharmDx 
(Dako, North America, Santa Barbara, CA, USA) is the gold standard (Figure 15) 
and is widely adopted in PD-L1 detection.
17.1 Limitations of PD-1/PD-L1 inhibitors
1. Before or throughout therapy with PD-1/PD-L1 inhibitors, variations of PD-L1 
expression in cancer cells might occur, causing different sensitivity to PD-1/
PD-L1 blockade, which might be missed by a single biopsy.
2. In the tissue microenvironment, cells like lymphocytes and macrophages, also 
express PD-L1.
3. Patients who receive immunotherapy are often in an advanced stage when  
tumors develop and evolve, and the PD-L1 expression in the primary tumor 
may have also changed dynamically. Some of the patients at these stages 
might not be able to tolerate the side effects caused by invasive tissue biopsy 
[114–117].
CTCs originate from different tumor sites and thus, better reflect the tumor het-
erogeneity compared to tissue biopsies. They could therefore be potentially useful 
as a non-invasive method to detect PD-L1 expression in NSCLC patients [114–120]. 
In 2016, Schehr et al. [121] reported the finding of PD-L1-positive (PD-L1+) CTCs 
in NSCLC via in-house immunomagnetic enrichment system. However, other than 
cells expressing EpCAM, the study also mentioned the co-isolation of CD11b+, 
CD45-low, and cytokeratin-positive (CK+)- cells that expressed PD-L1, that could 
be mislabeled as CTCs, thus stressing the importance of proper identification of 
CTCs to avoid false positive events. Recently, Wang et al. [122] mentioned the 
dynamic changes of PD-L1 expression by CTCs 13 non-metastatic NSCLC patients. 
CTCs were in all 13 samples, PD-L1+ CTCs were detected in 66.7% of the sample. A 
recent study from 106 NSCLC patients, showed a 93% concordance between PD-L1 
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status in CTCs and tumor tissue, indicating the potential of a CTC test in determin-
ing response to ICIs [120].
Another recent study used a novel SE-iFISH (subtraction enrichment interphase 
FISH) strategy to examine the presence of PD-L1 on aneuploid CTCs and aneuploid 
circulating tumor endothelial cells (CTECs) to evaluate if their presence could be 
used as a surrogate biomarker to evaluate the efficiency of second-line anti-PD-1 
(Nivolumab) immunotherapy. This study demonstrated that significant numbers of 
PD-L1+ aneuploid CTCs and CTECs could be detected in histopathologic hPD-L1- 
patients. In contrast to decreased PD-L1+ CTCs, the number of multiploid PD-L1+ 
CTECs (≥tetrasomy 8) undergoing post-therapeutic karyotype shifting increased 
in patients along with tumor progression following anti-PD-1 treatment and was 
associated with a significantly shorter PFS compared to those without PD-L1+ 
CTECs [123].
Many issues of PD-1/PD-L1 expression still need to be validated, including 
ensuring that the clones of antibody cocktail used for staining are standardized and 
equivalent in performance to the antibody clones included in the IHC kits that have 
received regulatory approval as companion diagnostics, as well as the threshold used 
to call a test PD-L1 positive, and whether the effect of the therapeutic use of anti-
PDL1 antibodies interferes with the binding of diagnostic PD-L1 antibodies on CTCs 
[124]. Currently there are over 400 listed clinical trials for LC patients using ICI’s 
alone or in combination with traditional chemotherapies [124]. Thus, if the CTC 
test, can be standardized, it will be of tremendous value as a complementary diag-
nostic tool for real time monitoring of PD-L1 expression for advanced lung cancer 
patients.
18. Conclusion
LB has evolved as a transformative technology for cancer diagnosis. Enormous 
strides have been made in recent years by the scientific and oncology communities 
to expand upon the tremendous value contained in a LB specimen. These readily 
obtained samples provide a real time window into the presence of cancer cells, 
the molecular evolution of the underlying tumor and its metastatic cascade and 
represent a far more feasible method for the longitudinal monitoring of the cancer 
patients as compared to direct tissue biopsy. Currently CTCs and ctDNA may be 
used in screening for early stage LC, as a diagnostic test to discriminate between 
a benign or malignant nodule on LDCT scan, as a decision –making tool or com-
panion diagnostic for instituting targeted therapy for different genetic mutations, 
for detecting the presence of minimum- residual disease and as a monitoring tool 
for detecting response to immune-check point inhibitors. There are however still 
discrepancies in how to harness the power of CTCs, especially in the area immune-
check point inhibitors, where standardization of CTC capture and companion PD-L1 
antibodies, together with inter-laboratory standardization in interpretation of these 
tests, will be mandatory. Another key objective of future research will be the ability 
to establish mouse models from CTCs to monitor the epigenetic, and genetic profil-
ing, functional and signaling pathways of malignant cells in response to different 
therapies. In order for LB for LC to become well accepted as a reliable source for 
actionable therapy large scale studies involving consortia of academic institutions 
and public/private partnerships are needed to establish reliable platforms for captur-
ing and detecting CTCs and ctDNA that validate pre-existing discovery studies. 
Notwithstanding these caveats, it is apparent that LB is becoming an indispensable 
weapon in the battle against cancer.
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